Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 153Lung Neoplasms 73Pancreatic Neoplasms 44Neoplasms 27Neoplasm Metastasis 25Head and Neck Neoplasms 23Brain Neoplasms 21Breast Neoplasms 18Glioblastoma 15Adenocarcinoma of Lung 15Squamous Cell Carcinoma of Head and Neck 14Gliosarcoma 14Adenocarcinoma, Bronchiolo-Alveolar 11Colorectal Neoplasms 10Glioma 9Carcinoma, Squamous Cell 8Carcinoma, Hepatocellular 8Adenocarcinoma 7Rectal Neoplasms 6Prostatic Neoplasms 6Esophageal Neoplasms 6Central Nervous System Neoplasms 6Carcinoma, Renal Cell 6Astrocytoma 6Oligodendroglioma 5Liver Neoplasms 5Colonic Neoplasms 5Carcinoma 5Recurrence 4Ovarian Neoplasms 4

Interventions

Adrenalectomy 4Radiosurgery 2Nivolumab 2Magnetic Resonance Spectroscopy 2Fluorodeoxyglucose F18 2FAPI-46 2pertuzumab 1olaparib 1lutetium Lu 177 dotatate 1iodophenyl metomidate 1camrelizumab 1apatinib 1X-Rays 1Radiofrequency Ablation 1Nephrectomy 1Mitotane 1Gefitinib 1Erlotinib Hydrochloride 1Endosonography 1Endoscopic Ultrasound-Guided Fine Needle Aspiration 1Cystectomy 1Cryosurgery 1Adosterol 1(18F)GTP1 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Adrenal Gland Neoplasms × Erlotinib Hydrochloride × Clear all
NCT00947167 2017-03-03

A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors

Stanford University

Phase 2 Terminated
4 enrolled 5 charts
CNSEndocrineNET

Adrenal Gland Neoplasms, Carcinoid Tumor, Multiple Endocrine Neoplasia, Neuroblastoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡